Ironwood Pharma (IRWD) Plans to Separate Could Unlock Value of Linzess Profit Stream - BTIG

May 1, 2018 1:48 PM

BTIG analyst Timothy Chiang reiterated a Buy rating and $21 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD) saying the company's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found